MARCOS
GONZÁLEZ DÍAZ
Investigador en el periodo 1993-2023
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (20)
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
2021
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
2019
-
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491
2016
-
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924
-
Sarcoma histiocítico en intestino delgado: estudio y discusión de un caso con reordenamiento clonal linfoide B
Revista Espanola de Patologia, Vol. 49, Núm. 4, pp. 254-258
2015
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805
-
Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica
Gaceta Sanitaria, Vol. 25, Núm. 4, pp. 274-281
-
Fe de errores de "Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica"
Gaceta Sanitaria
-
Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: A 3-year GETMON experience
Bone Marrow Transplantation, Vol. 46, Núm. 1, pp. 119-124
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2010
-
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Haematologica, Vol. 95, Núm. 3, pp. 424-431
-
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, Vol. 95, Núm. 1, pp. 87-95
-
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
Blood, Vol. 116, Núm. 25, pp. 5650-5659
-
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: A study of the Spanish PETHEMA group
Haematologica, Vol. 95, Núm. 8, pp. 1317-1324
2009
-
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Haematologica, Vol. 94, Núm. 9, pp. 1242-1249
-
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
Blood, Vol. 113, Núm. 4, pp. 775-783
2008
-
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
Blood, Vol. 111, Núm. 7, pp. 3395-3402
-
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
Blood, Vol. 112, Núm. 8, pp. 3130-3134
2005
-
Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: A report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH)
Bone Marrow Transplantation, Vol. 36, Núm. 9, pp. 781-785